Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 8/20 | 1.00 |
| ▸ | TPO | P07202 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14936473 | 0.99 | MPO (0.98) | MPOTPOGRIN1GRIN2BKDM4E | |
| SCHEMBL14936413 | 0.95 | MPO (0.91) | MPOTPOGRIN1GRIN2BKDM4E | |
| SCHEMBL14936646 | 0.92 | MPO (0.86) | MPOTPOGRIN1GRIN2BKDM4E | |
| SCHEMBL14936381 | 0.91 | MPO (0.84) | MPOTPOGRIN1GRIN2BKDM4E | |
| SCHEMBL14936710 | 0.91 | MPO (0.84) | MPOTPOGRIN1GRIN2BKDM4E | |
| SCHEMBL14936305 | 0.91 | MPO (0.83) | MPOTPOGRIN1GRIN2BKDM4E | |
| SCHEMBL14936061 | 0.91 | MPO (0.83) | MPOTPOKDM4EALDH1A1LMNA | |
| SCHEMBL14936268 | 0.90 | MPO (0.82) | MPOTPOGRIN1GRIN2BKDM4E | |
| SCHEMBL14936337 | 0.90 | MPO (0.82) | MPOTPOGRIN1GRIN2BKDM4E | |
| SCHEMBL14936569 | 0.90 | MPO (0.82) | MPOTPOGRIN1GRIN2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | claimed |
| US-20160304469-A1 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2016-10-20 | — | — | US | claimed |
| US-9399626-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2016-07-26 | — | — | US | claimed |
| US-20140288049-A1 | 2-Thiopyrimidinones | PFIZER (US) | 2014-09-25 | — | — | US | claimed |
| US-8841314-B2 | 2-Thiopyrimidinones | PFIZER INC. (US) | 2014-09-23 | — | — | US | claimed |
| EP-2776405-A1 | 2-THIOPYRIMIDINONES | Pfizer Inc (US) | 2014-09-17 | — | — | EP | claimed |
| US-20130296351-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-11-07 | — | — | US | claimed |
| WO-2013068875-A1 | 2-THIOPYRIMIDINONES | PFIZER INC. (US) | 2013-05-16 | — | — | WO | claimed |
| EP-3292109-A1 | 2-THIOPYRIMIDINONES | Pfizer Inc (US) | 2018-03-14 | — | — | EP | disclosed |
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873673-B2 | 2-thiopyrimidinones | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170275257-A1 | 2-THIOPYRIMIDINONES | PFIZER INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275257-A1 | 2-THIOPYRIMIDINONES | PFIZER INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20130296351-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130123230-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130123230-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-05-16 | — | — | US | disclosed |
| US-20130123230-A1 | 2-Thiopyrimidinones | PFIZER INC. | 2013-05-16 | — | — | US | disclosed |
| WO-2013068875-A1 | 2-THIOPYRIMIDINONES | PFIZER INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013068875-A1 | 2-THIOPYRIMIDINONES | PFIZER INC. (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123230-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885GRIN1 2771/4885 |
| US-20160304469-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885GRIN1 2771/4885 |
| US-20170275257-A1 | 2-THIOPYRIMIDINONES | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885GRIN1 2547/4885 |
| US-20140288049-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885GRIN1 2771/4885 |
| US-20130296351-A1 | 2-Thiopyrimidinones | MPO, SERPINB1, TNNI3 | MPO 1/4885TPO 32/4885GRIN1 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.